Highlights

  • PYC Therapeutics has commenced a Phase 1b Multiple Ascending Dose study for its PKD drug candidate PYC-003.
  • The first patient enrolled in the study has now received the investigational treatment.
  • The study will evaluate safety, tolerability and several efficacy-related endpoints in PKD patients.
  • Key measures include urinary PC1 protein levels, total kidney Volume and estimated glomerular filtration rate.
  • Data from the ongoing Phase 1a study is expected in the second half of calendar year 2026.

PYC Therapeutics Ltd (ASX:PYC) has announced another development milestone within its Polycystic Kidney Disease program, with the biotechnology company confirming commencement of a Phase 1b Multiple Ascending Dose study for its investigational drug candidate PYC-003.

The Company stated on 7 May 2026 that the first patient enrolled in the study has now received an initial dose of the treatment candidate, marking the beginning of the next stage of clinical evaluation for the program.

Shares of PYC Therapeutics traded at AUD 1.18 on 7 May 2026, up 1.29% for the session. Despite the daily gain, the stock remains approximately 7.81% lower over the past 12 months as investors continue monitoring clinical development milestones across the Company’s pipeline.

The latest update represents another step in PYC’s broader effort to develop RNA-based precision medicines targeting genetic diseases with limited treatment Options.

PYC Therapeutics is a clinical-stage biotechnology company focused on RNA therapeutics and precision medicine technologies. The Company’s development programs target monogenic diseases, where treatments are designed to address the underlying genetic cause of disease progression.

Among its active pipeline Assets is PYC-003, which is being developed as a potential treatment for Polycystic Kidney Disease, commonly referred to as PKD.

Phase 1b Study Commences with First Patient Dosed

According to the Company, the newly commenced Phase 1b trial is an open-label Multiple Ascending Dose study involving PKD patients.

The objective of the study is to evaluate the safety and tolerability profile of PYC-003 in a repeat-dose setting while also assessing several endpoints linked to potential treatment activity.

PYC confirmed that dosing of the first patient enrolled in the trial has already been completed.

The Company stated that the study is expected to provide information regarding the optimal repeat dosing regimen for the investigational therapy ahead of potential progression into later-stage clinical studies.

The latest trial follows the ongoing Phase 1a Single Ascending Dose study currently being conducted in PKD patients.

Management indicated that successful completion of the Phase 1b study, together with future regulatory discussions, could support progression toward a combined registrational Phase 2/3 study.

Focus on Safety and Disease-Related Biomarkers

The Company outlined several endpoints that are expected to be evaluated during the Multiple Ascending Dose study.

One of the primary areas of focus will be safety and tolerability assessment in patients receiving repeated doses of the investigational therapy.

In addition, the study is expected to examine urinary PC1 protein levels, which PYC believes may act as a biomarker linked to kidney PC1 protein expression.

The Company stated that the objective of PYC-003 is to increase PC1 protein expression within the kidneys.

Beyond biomarker analysis, the trial is also expected to evaluate total kidney volume using MRI imaging techniques.

Estimated glomerular filtration rate, commonly used as a measure of kidney function, will also be assessed in patients enrolled in the study.

According to the Company, analysis of kidney function data is expected to be evaluated within the context of a planned open-label extension study linked to the Phase 1b trial.

Potential Pathway Toward Registrational Study

PYC stated that the Multiple Ascending Dose study forms part of its broader proposed clinical development pathway for PYC-003.

The Company indicated that successful completion of the trial, combined with regulatory alignment, could support commencement of a combined Phase 2/3 registrational study intended to support a future New Drug Application.

Registrational studies generally represent later-stage Clinical Trials designed to generate data required for regulatory review and potential commercial approval.

However, the Company also noted that future development timelines remain subject to ongoing study outcomes, regulatory engagement and broader clinical development risks previously outlined in its ASX disclosures.

Biotechnology investors often closely monitor transitions between early-stage clinical studies and potential registrational pathways, as these milestones can influence future commercial development opportunities.

Data Timelines Remain Key Investor Focus

PYC provided updated guidance regarding expected data release timelines for both ongoing clinical studies within the PKD program.

According to the Company, data from the ongoing Phase 1a Single Ascending Dose study is expected to be presented during the second half of calendar year 2026.

Meanwhile, data from the Phase 1b Multiple Ascending Dose study is currently expected to be presented during calendar year 2027.

These timelines are likely to remain an important area of focus for investors tracking progress across the Company’s clinical pipeline.

Clinical-stage biotechnology companies are often assessed based on the progression of development milestones, patient enrolment activity, safety observations and future efficacy indicators generated during trials.

As a result, future updates associated with dosing progression, patient recruitment and study outcomes may continue to influence broader market attention toward PYC’s development programs.

PYC Continues Building RNA Therapeutics Platform

PYC Therapeutics continues positioning itself within the growing RNA therapeutics sector, an area that has attracted increasing industry and investor attention over recent years.

The Company stated that its development strategy centres around a proprietary drug delivery platform designed to improve potency of precision RNA medicines.

PYC currently has three clinical-stage development programs targeting genetic diseases where existing treatment options are limited or unavailable.

Its focus on monogenic diseases reflects an area often viewed within biotechnology as potentially offering clearer disease mechanisms and targeted therapeutic opportunities.

The Company believes its platform may support the development of therapies capable of addressing underlying genetic drivers rather than solely managing disease symptoms.

Within the PKD program specifically, PYC-003 is being developed to address the underlying biological cause of disease progression associated with reduced PC1 protein expression.

Understanding Polycystic Kidney Disease

Polycystic Kidney Disease is a genetic disorder characterised by the development of fluid-filled cysts within the kidneys, which can progressively impair kidney function over time.

As the disease advances, patients may experience declining kidney function and complications associated with enlarged kidneys.

The Company’s investigational approach focuses on increasing PC1 protein expression within the kidneys, which it believes may help address underlying disease mechanisms.

Biomarker monitoring and imaging endpoints included within the current study are intended to help assess both biological activity and disease-related changes during treatment evaluation.

While early-stage studies are generally focused primarily on safety and dosing, efficacy-related measurements can provide preliminary insight into how a therapy may be performing during clinical development.

Investors Watching Upcoming Clinical Milestones

The commencement of the Multiple Ascending Dose study represents another operational milestone for PYC’s PKD program, particularly as the Company continues advancing multiple clinical-stage assets.

Market attention is likely to remain focused on future patient enrolment progress, dosing updates and upcoming data releases scheduled across 2026 and 2027.

The Company’s proposed transition pathway toward a future registrational study may also remain an area of interest for investors following the broader commercial potential of the PYC-003 program.

At the same time, biotechnology development remains inherently linked to regulatory, clinical and scientific uncertainty, with future outcomes dependent on ongoing trial performance and broader regulatory engagement.

For now, the latest announcement signals continued advancement of PYC’s clinical development activities as the Company progresses evaluation of its RNA-based therapeutic candidate in patients with Polycystic Kidney Disease.